Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Engineering Functionality Optimized fully human B7-H3 CAR T Cells for Enhanced Solid Tumor Therapy.

bioRxiv : the preprint server for biology·2026

Same author

Dissection of Gαs and Hedgehog Signaling Cross-talk Reveals Therapeutic Opportunities to Target Hedgehog-Dependent Tumors.

Cancer research·2025

Same author

GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts.

Molecular therapy. Oncology·2025

Same author

ANTXR1 blockade enhances cardiac function in preclinical models of heart failure.

Nature cardiovascular research·2025

Same author

A review of diffuse hemispheric glioma, H3 G34-mutant disease development, DNA repair, microenvironment, and treatments on the horizon.

NPJ precision oncology·2025

Same author

m276-SL-PBD eradicates tumors and instigates long-lasting tumor-free survival in Merkel cell carcinoma preclinical models.

iScience·2025

Same journal

Multi-omics profiling unveils biological and clinical insights into pulmonary sarcomatoid carcinoma.

Cell reports. Medicine·2026

Same journal

Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4<sup>+</sup>CD8<sup>+</sup> T cells.

Cell reports. Medicine·2026

Same journal

Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors.

Cell reports. Medicine·2026

Same journal

Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions.

Cell reports. Medicine·2026

Same journal

A S.C.O.R.E. framework for evaluating open-ended responses from large language models in healthcare.

Cell reports. Medicine·2026

Same journal

GPNMB<sup>+</sup> macrophages promote osteogenic differentiation of nucleus pulposus cells through PDGF signaling in intervertebral disc degeneration.

Cell reports. Medicine·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 2, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Engineering functionality-optimized fully human B7-H3 CAR T cells for enhanced solid tumor therapy.

Pradip Bajgain¹, Yang Feng¹, Mariela Puebla²

¹Tumor Angiogenesis Unit, Mouse Cancer Genetics Program, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Frederick, MD 21702, USA.

Cell Reports. Medicine

|April 30, 2026

Summary

This summary is machine-generated.

A novel fully human B7-H3 specific antibody fragment, Y111, shows superior efficacy in preclinical models. This breakthrough offers improved chimeric antigen receptor (CAR) T cell therapy for solid tumors, overcoming limitations of existing treatments.

Keywords:

B7-H3 B7H3 CAR CD276 adoptive T cell transfer chimeric antigen receptor fully human antibody glioblastoma neuroblastoma pancreatic ductal adenocarcinoma phage display library

More Related Videos

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: May 2, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

Oncology
Immunotherapy
Biotechnology

Background:

B7-H3 is a cell surface protein frequently overexpressed in solid tumors.
Current chimeric antigen receptor (CAR) T cell therapies targeting B7-H3 utilize murine-derived antibodies, risking immune rejection.
Existing humanized CARs may still contain immunogenic residues.

Purpose of the Study:

To develop fully human single-chain variable fragments (scFvs) for B7-H3 CAR T cell therapy.
To evaluate the safety and efficacy of a novel human B7-H3 CAR T cell therapy in preclinical cancer models.

Main Methods:

In vitro phage display was used to generate fully human B7-H3-specific scFvs.
CAR T cells incorporating the lead human binder, Y111, were tested in pancreatic cancer, neuroblastoma, and glioblastoma xenograft models.
Comparative analysis with existing B7-H3 CARs (376.96 and MGA271) was performed.

Main Results:

CAR T cells with the Y111 binder were well-tolerated in xenograft models.
Y111-based CAR T cells demonstrated superior antitumor activity compared to murine-derived CARs.
Complete tumor responses, rejection, and significant survival benefits were observed with Y111 CAR treatment.

Conclusions:

The fully human B7-H3 binder Y111 is a promising candidate for next-generation CAR T cell therapy.
Y111 CAR T cells offer enhanced safety and efficacy for treating solid tumors.
This approach overcomes immunogenicity issues associated with non-human CAR components.